Stem Cell and Derivatives
Stem cell inhibitors are compounds that specifically target signaling pathways and proteins involved in the maintenance, differentiation, and proliferation of stem cells. These inhibitors are crucial for understanding stem cell biology and for developing strategies to manipulate stem cells for therapeutic purposes, such as regenerative medicine and cancer treatment. By controlling stem cell fate, these inhibitors can help guide stem cell differentiation into specific cell types or prevent unwanted cell growth. At CymitQuimica, we offer a selection of high-quality stem cell inhibitors to support your research in stem cell biology, developmental biology, and regenerative medicine.
Subcategories of "Stem Cell and Derivatives"
- Gamma-secretase(59 products)
- Hedgehog/Smoothened(44 products)
- Hippo pathway(6 products)
- JAK(245 products)
- Porcupine(9 products)
- ROCK(69 products)
- STAT(98 products)
- Stem Cells(484 products)
- TGF-beta/Smad(58 products)
- Wnt/beta-catenin(66 products)
Show 2 more subcategories
Found 693 products of "Stem Cell and Derivatives"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK-IN-3
CAS:<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Formula:C18H20N4O3Purity:98.04% - 98.19%Color and Shape:SolidMolecular weight:340.38GSK-3 inhibitor 1
CAS:<p>GSK-3 inhibitor 1 is a GSK-3 inhibitor.</p>Formula:C22H17ClFN5O2Purity:98.42%Color and Shape:SolidMolecular weight:437.85JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formula:C29H25N7O6SColor and Shape:SolidMolecular weight:599.62Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.42Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formula:C21H25F2N7OColor and Shape:SolidMolecular weight:429.47TEAD-IN-20
CAS:<p>TEAD-IN-20 is a TEAD inhibitor with IC50 values of 0.021 μM in TEAD4 FRET and 0.044 μM in TEAD4 MCF7-Tead cell lines. It has potential applications in cancer research.</p>Formula:C20H19F3N4O3Color and Shape:SolidMolecular weight:420.39JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formula:C23H22Cl2N4OColor and Shape:SolidMolecular weight:441.35Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formula:C18H20F6N4OColor and Shape:SolidMolecular weight:422.37(+)-ITD-1
CAS:<p>(+)-ITD-1 is an inhibitor of TGF-β, effectively inhibiting TGF-β2 with an IC50 of 0.46 μM. It promotes the degradation of the TGF-β type II receptor (TGFBR2) and the differentiation of cardiomyocytes. Additionally, it suppresses the formation of the mesoderm during the early differentiation of mouse embryonic stem cells (mESCs).</p>Formula:C27H29NO3Color and Shape:SolidMolecular weight:415.52JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Color and Shape:SolidCDK8-IN-11
CAS:<p>CDK8-IN-11 is a CDK8 inhibitor that demonstrates anti-proliferative activity against colon cancer cell lines and inhibits the activation of WNT/β-catenin.</p>Formula:C19H15F3N4O2Purity:99.74%Color and Shape:SolidMolecular weight:388.34CEE321
CAS:<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formula:C18H16ClN5OColor and Shape:SolidMolecular weight:353.806TEAD-IN-10
CAS:<p>TEAD-IN-10 (compound 15), a covalent inhibitor, exhibits selective and potent inhibitory activity against TEAD1 (IC 50 =14 nM), TEAD2 (IC 50 =179 nM), and TEAD3 (IC 50 =4 nM). This compound is utilized in cancer research [1].</p>Formula:C15H14F3NOColor and Shape:SolidMolecular weight:281.27Londamocitinib
CAS:<p>Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.</p>Formula:C28H31F2N7O4SPurity:98.64% - 99.56%Color and Shape:SolidMolecular weight:599.65PMMB-187
CAS:<p>PMMB-187, a selective STAT3 inhibitor, exhibits an IC50 of 1.81 μM in MDA-MB-231 cells. This compound induces apoptosis in MDA-MB-231 cells by inhibiting STAT3 transcriptional activity and nuclear translocation, reducing mitochondrial membrane potential, increasing reactive oxygen species (ROS) production, and upregulating the expression of apoptosis-related proteins. PMMB-187 is useful for research in the field of cancer.</p>Formula:C27H23BrN2O6S2Color and Shape:SolidMolecular weight:615.52(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Formula:C20H27ClN6OColor and Shape:SolidMolecular weight:402.92Tyk2-IN-14
CAS:<p>Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].</p>Formula:C22H21N9O2Color and Shape:SolidMolecular weight:443.46γ-Secretase modulator 11 hydrochloride
CAS:<p>γ-Secretase modulator 11 hydrochloride is a potent, orally active γ-secretase modulator (IC50: 0.029 μM).</p>Formula:C28H23ClF2N4O2Color and Shape:SolidMolecular weight:520.96Notch inhibitor 1
CAS:<p>Notch inhibitor 1 blocks Notch 1/3 (IC50: 7.8/8.5 nM) and aids cancer research.</p>Formula:C26H25F7N4O3Purity:98%Color and Shape:SolidMolecular weight:574.49Tyk2-IN-20
CAS:<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Formula:C24H25N7O2Color and Shape:SolidMolecular weight:443.50Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40DAPM
CAS:<p>DAPM (gamma-Secretase Inhibitor XVI) is a Notch pathway inhibitor with anticancer activity and antiproliferative effects.</p>Formula:C20H20F2N2O4Purity:99.76%Color and Shape:SolidMolecular weight:390.38YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Formula:C32H34F3N7O2Color and Shape:SolidMolecular weight:605.65LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formula:C26H31N7O2Color and Shape:SolidMolecular weight:473.57GSK-3β inhibitor 20
CAS:<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Formula:C22H21N5O2SColor and Shape:SolidMolecular weight:419.50STAT3-IN-35
CAS:<p>STAT3-IN-35 is a STAT3 inhibitor that binds to the SH2 domain. This compound inhibits the phosphorylation of STAT3 and exhibits antiproliferative activity in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 has demonstrated toxicity and potent antitumor activity in TNBC xenograft models.</p>Formula:C21H23NO4Color and Shape:SolidMolecular weight:353.41JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Formula:C17H20N6OPurity:98.81%Color and Shape:SolidMolecular weight:324.38AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Formula:C17H14FN5OColor and Shape:SolidMolecular weight:323.32AZ-3
CAS:<p>AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).</p>Formula:C20H28FN7Purity:98%Color and Shape:SolidMolecular weight:385.48JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Formula:C31H31F3N8O4Color and Shape:SolidMolecular weight:639.64Aβ42-IN-1
CAS:<p>Aβ42-IN-1, compound 1v, is a novel, potent and orally active γ-secretase modulator (GSM).</p>Formula:C29H27ClN4O2Purity:98%Color and Shape:SolidMolecular weight:499BPN-15606 besylate
<p>BPN-15606 besylate is a potent oral γ-secretase regulator reducing Aβ42 and Aβ40 with good pharmacokinetics. IC50: 7 nM (Aβ42), 17 nM (Aβ40).</p>Formula:C29H29FN6O4SColor and Shape:SolidMolecular weight:576.64HDAC6-IN-9
CAS:<p>HDAC6-IN-9 is a γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.</p>Formula:C19H16N2O3Purity:98.84%Color and Shape:SolidMolecular weight:320.34AJI-214
CAS:<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Formula:C17H13ClFN5OColor and Shape:SolidMolecular weight:357.77JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Formula:C22H17FN6O2SPurity:98%Color and Shape:SolidMolecular weight:448.47YAP/TAZ-TEAD-IN-2
<p>YAP/TAZ-TEAD-IN-2 (Compound 51) is a YAP/TAZ-TEAD inhibitor that disrupts the interaction between YAP/TAZ and TEAD. It inhibits the transcriptional activity of TEAD with an IC50 of 1.2 nM. Additionally, YAP/TAZ-TEAD-IN-2 suppresses the expression of target genes (Cyr61, CTGF, AXL, and Survivin) and the proliferation of breast cancer cells.</p>Formula:C19H20N2O3SColor and Shape:SolidMolecular weight:356.44YAP/TAZ inhibitor-3
CAS:<p>YAP/TAZ inhibitor-3 (Compound 24) is a YAP/TAZ inhibitor applicable for relevant research within the life sciences field.</p>Formula:C21H18F3NO3Purity:99.63%Color and Shape:SolidMolecular weight:389.37CP-352664
CAS:<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formula:C18H18N4Color and Shape:SolidMolecular weight:290.36TGFβ1-IN-1
CAS:<p>TGFβ1-IN-1 is a TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in cancer research.</p>Formula:C22H24N2O3Purity:99.89% - 99.89%Color and Shape:SolidMolecular weight:364.438JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Formula:C20H15ClF3N3OSColor and Shape:SolidMolecular weight:437.87Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Formula:C25H24N6O3S2Purity:98%Color and Shape:SolidMolecular weight:520.63ROCK/HDAC-IN-1
<p>ROCK/HDAC-IN-1 (Compound 10h) serves as an orally effective inhibitor of ROCK/HDAC. This compound suppresses ROCK1/2 (IC50: 254.9 nM, 58.18 nM) and HDAC1/2/3/6/8 (IC50: 9.09, 8.03, 6.26, 0.41, 7.69 nM). It stimulates the activation of DAMPs, notably calreticulin (CRT) exposure and HMGB1 release, suggesting its potential as an inducer of immunogenic cell death (ICD). ROCK/HDAC-IN-1 exhibits antiproliferative effects against breast cancer cells (IC50: 0.37 μM for MDA-MB-231 cells), inhibits tumor growth, activates T cells, and shows no significant toxicity.</p>Formula:C19H22N4O3SColor and Shape:SolidMolecular weight:386.47JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Formula:C17H23N7OColor and Shape:SolidMolecular weight:341.41(Rac)-SAG
CAS:<p>(Rac)-SAG, an isoform of SAG, is a potent Smoothened (Smo) receptor agonist (EC₅₀ = 3 nM; Kd = 59 nM) that activates the Hedgehog signaling pathway and counteracts Cyclopamine's inhibition of Smo [1] [2] [3].</p>Formula:C28H28ClN3OSColor and Shape:SolidMolecular weight:490.06STAT3-IN-8
CAS:<p>"STAT3-IN-8 (compound H172) is a potent inhibitor of STAT3 with potential applications in cancer research [1]."</p>Formula:C19H7F7N2O3Purity:98%Color and Shape:SolidMolecular weight:444.26MGD-28
CAS:<p>MGD-28 is a Cullin-CRBN-dependent IKZF family protein degrader for IKZF1 (Ikaros), IKZF2 (Helios), IKZF3 (Aiolos) ,and CK1α, antiproliferative.</p>Formula:C33H34FN7O3Purity:99.39%Color and Shape:SolidMolecular weight:595.67MYF-03-176
CAS:<p>MYF-03-176 is an orally active TEAD1/3/4 inhibitor with IC₅₀ values of 47/32/71 nM. inhibits TEAD transcriptional activity and cancer cell growth, antitumour.</p>Formula:C19H18F4N4O2Color and Shape:SolidMolecular weight:410.37JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formula:C16H13IN6Color and Shape:SolidMolecular weight:416.22STAT3-IN-36
CAS:<p>STAT3-IN-36 (compound 11g) is a tritarget inhibitor that selectively targets LRPPRC, STAT3, and CDK1, exhibiting potent anticancer activity. This compound binds to LRPPRC, STAT3, and CDK1, demonstrating more effective anticancer effects than those of TMF or Capecitabine. Additionally, STAT3-IN-36 exhibits an IC50 value of 1.8 μM in HGC27 cells.</p>Formula:C30H24F2N2O9S2Color and Shape:SolidMolecular weight:658.65PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Formula:C31H31FN8O2Purity:98%Color and Shape:SolidMolecular weight:566.63
